Last Updated: Tuesday, June 11, 2013
Principal Investigator: Jeremy M. Veenstra-VanderWeele, M.D.
Other researchers: Cassandra Newsom, PhD Kevin Sanders, MD
The purpose of this study is to try to find out if an investigational drug, AFQ056, is helpful in treating the problem behaviors often associated with Fragile X syndrome. The study will also try to figure out if AFQ056 is safe and able to be tolerated.
Evaluations, study visits, and study drug are provided at no cost. Compensation for transportation costs and time will also be provided.
You will be asked to come for 12 visits to Vanderbilt University in Nashville, TN. to take part in this research study. A blood draw is required at 10 separate visits.
Children with a confirmed diagnosis of Fragile X between 3 and 11 years.
Compensation for travel, visits, evaluations and medication.
12 visits to Vanderbilt Children's Hospital
Adolescents (12-17 years old) with Fragile X syndromeCompensation: Yes
Adults age 14– 50 with Fragile X for a study using an investigational drug.Compensation: Yes
People with Fragile X age 5-13Compensation: Yes
Children age 6– 17 with an autism spectrum disorder who are taking an atypical antipsychotic like Risperidone (risperidol), Zyprexa (Olanzapine) and have gained unwanted weight.Compensation: Yes
Children age 6-18 with autism spectrum disorders with and without GI problems.Compensation: Yes
Males ages 18-45 with diagnosis of autism spectrum disorder. Must be verbal.Compensation: Yes
Visit this investigator's people page to list all of their studies together.